Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: MacroGenics, Inc.

Market Cap 26Cr 23Cr 21Cr 20Cr 37Cr 2.48TCr 37Cr 251.48Cr 97Cr 1.22TCr 99Cr 96Cr 4.23TCr P/E 2026 *
-6.16x
P/E 2027 * -2.7x
Enterprise Value 26Cr 23Cr 21Cr 20Cr 37Cr 2.48TCr 37Cr 251.48Cr 97Cr 1.22TCr 99Cr 96Cr 4.23TCr EV / Sales 2026 *
1.6x
EV / Sales 2027 * 2.79x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+4.29%
1 week+4.29%
Current month-0.72%
1 month-8.63%
3 months+42.41%
6 months+175.33%
Current year+156.52%
1 week 3.84
Extreme 3.845
4.24
1 month 3.81
Extreme 3.81
4.64
Current year 1.58
Extreme 1.58
4.64
1 year 1.18
Extreme 1.185
4.64
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/05Free

Founder

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+4.29%+4.29%+201.46%-32.52% 26Cr
+1.44%-1.25%+63.52%+114.88% 5.52TCr
+4.60%+3.02%+58.20%+47.16% 4.58TCr
-1.44%+0.39%-12.94%-19.24% 2.3TCr
-2.69%-2.10%-3.68%+379.00% 2.08TCr
+3.22%-0.84%+27.88%-34.00% 1.63TCr
+0.58%+1.08%+16.73%-38.06% 1.54TCr
-1.01%-2.30%+27.42%+171.92% 1.3TCr
+4.95%+11.70%+123.63%+252.19% 1.24TCr
+3.07%+0.14%+29.37% - 1.24TCr
Average +1.70%+2.31%+53.16%+93.48% 2.14TCr
Weighted average by Cap. +1.63%+1.48%+41.11%+99.74%

Financials

2026 *2027 *
Net sales 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 157.48Cr 61Cr 763.5Cr 62Cr 60Cr 2.65TCr 9.43Cr 8.22Cr 7.61Cr 7.13Cr 13Cr 889.42Cr 13Cr 90Cr 35Cr 437.79Cr 35Cr 35Cr 1.52TCr
Net income -1.83Cr -1.6Cr -1.48Cr -1.38Cr -2.6Cr -172.73Cr -2.61Cr -18Cr -6.8Cr -85Cr -6.87Cr -6.72Cr -295.2Cr -13Cr -11Cr -10Cr -9.6Cr -18Cr -1.2TCr -18Cr -121.7Cr -47Cr -590.01Cr -48Cr -47Cr -2.05TCr
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
18/26/18 4.130 $ +4.29% 9,73,000
17/26/17 3.960 $ +2.06% 6,49,604
16/26/16 3.880 $ -6.05% 5,48,417
15/26/15 4.130 $ +4.29% 6,20,482
12/26/12 3.960 $ -1.25% 5,13,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.130USD
Average target price
6.750USD
Spread / Average Target
+63.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!